Fujirebio Diagnostics, Incorporated
$2.2M 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ceribell, Inc.
Ceribell, Inc. reported $2,268,256.09 across General Payments, Research, and Ownership to 1,173 physicians and teaching hospitals across 1,180 transactions.
- $2.3M Top quartile payer
- All-tracks total
- 1,180 Above-median volume
- Transactions
- 1,173 Above-median reach
- Recipients
- +$614.0K
- General Payments vs PY2023
Ceribell, Inc. reported $2,268,256.09 across all CMS Open Payments tracks (General + Research + Ownership) to 1,173 physicians and teaching hospitals in Program Year 2024 - ranking #423 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,887,429.81, averaging $1.9K per recipient.
How Ceribell, Inc.'s $2.3M all-tracks total breaks down
Ceribell, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
27/100
Total payments
F
31/100
Transaction volume
F
19/100
Physician reach
F
19/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ceribell-inc Ceribell, Inc.
$2.3M · #423/1,925 · 0.0% industry · PY2024
- TOT $2.3M
- RANK #423
- SHARE 0.0%
- TXN 1,180
- RCP 1,173
- CAT 3
- GEN $1.9M
- ΔGEN +$614.0K
- TOP1 19.6%
- PY 2024
Volume peers
Nearest volume peer: Fujirebio Diagnostics, Incorporated ($2.2M)
Ceribell, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ceribell, Inc.'s CMS-reported General Payments increased by $614.0K (+48.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CERIBELL, INC.PY2023: CERIBELL, INC.PY2024: Ceribell, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,273,417.48
- PY2024
- $1,887,429.81
What the Data Shows for Ceribell, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Ceribell, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
289 transactions worth $1.8M make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 95.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Ceribell, Inc.'s largest category was "Consulting Fee" at $1.8M - 95.9% of General Payments.
How Ceribell, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.8M | 289 | 95.9% |
| Food and Beverage | $51.6K | 853 | 2.7% |
| Travel and Lodging | $25.9K | 31 | 1.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $988,214.28 (52.4%) of $1,887,429.81 in this company's General Payments records across 793 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ceribell, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Parshaw Jonathan Dorriz
$369,582.91 across 27 reported transactions
- 2
Josef Parvizi
$208,023.61 across 29 reported transactions
- 3
Audrey R Nath
$178,700.00 across 12 reported transactions
- 4
Margo L Block
$120,782.76 across 11 reported transactions
- 5
John M Stern
$111,125.00 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ceribell, Inc. ranks #423 of 1,925 by total payments (top 22% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,132 of 1,838 by HHI (bottom 38% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Vapotherm Inc : $135.8K total payments, HHI 783
- Genzyme Corporation : $57.6M total payments, HHI 783
- Heraeus Medical, LLC. : $35.7K total payments, HHI 783
- Wilson Cook Medical Incorporated : $646.8K total payments, HHI 783
- Cosa Medical, Llc : $4.3K total payments, HHI 782
- Gen-Probe, Inc. : $641.0K total payments, HHI 781
- Ceribell, Inc. (this company) : $1.9M total payments, HHI 781
- Shofu Dental Corp : $101.9K total payments, HHI 777
- G Medical Diagnostic Services, Inc. : $1.5K total payments, HHI 776
- Spine Wave, Inc. : $326.4K total payments, HHI 775
- Spineart SA : $2.0M total payments, HHI 775
- Theratechnologies Inc. : $330.9K total payments, HHI 772
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ceribell, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ceribell, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ceribell, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Orchard Therapeutics North America
$2.2M 69 recipients
Compare payment profiles
Aimmune Therapeutics, Inc.
$2.3M 32,592 recipients
Compare payment profiles
Ethicon Endo-Surgery Inc.
$2.3M 150 recipients
Compare payment profiles
New World Medical,inc.
$2.2M 3,180 recipients
Compare payment profiles
Albireo Pharma, Inc.
$2.3M 371 recipients
Compare payment profiles
Put this to use
Ceribell, Inc. ranks #423 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Ceribell, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Ceribell, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.